Table 3.
Prevalence rate and quality score of the studies in the meta-analysis by prevalence (n=15).
| Study | Sample size (n) | HEV IgG positive (n) | Prevalence (%) | Quality score (average) | Ref. |
|---|---|---|---|---|---|
| Musa | 93 | 57 | 61.29 | 7 | 37 |
| Niguse | 846 | 359 | 42.43 | 8 | 49 |
| Abebe | 386 | 122 | 31.61 | 8 | 46 |
| Tekeste | 153 | 41 | 26.80 | 6 | 47 |
| De Paschale | 278 | 62 | 22.30 | 7 | 41 |
| Rui | 225 | 49 | 21.78 | 7 | 48 |
| Cong | 990 | 161 | 16.26 | 7 | 38 |
| Obiri-Yeboah | 398 | 48 | 12.06 | 8 | 50 |
| Gu | 497 | 55 | 11.07 | 7 | 39 |
| Florence | 179 | 19 | 10.61 | 6 | 44 |
| Alkali | 182 | 18 | 9.89 | 6 | 43 |
| Noufensi | 200 | 18 | 9.00 | 6 | 42 |
| Mamani | 1050 | 78 | 7.43 | 8 | 37 |
| Farshadpour | 1331 | 83 | 6.24 | 8 | 51 |
| La Fauci | 352 | 12 | 3.41 | 6 | 45 |